Bones & muscles GHRH analog (secretagogue)
CJC-1295
Regulatory status
Status at a glance
503A compounding status
Removed from Category 2 (review pending)
FDA has moved this substance out of Category 2 while it is reviewed further. Removal from Category 2 does not authorize compounding. Its status remains unsettled until FDA completes its evaluation.
- FDA approval
- Not FDA-approved for any use
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- On the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
CJC-1295 is a synthetic long-acting analog of growth-hormone-releasing hormone (GHRH). In two placebo-controlled trials of healthy adults aged 21 to 61 (Teichman, 2006), a single injection raised mean growth hormone 2- to 10-fold for 6 days or more. Mean IGF-1 rose 1.5- to 3-fold, but no controlled human trial shows benefit for muscle, fat loss, recovery, or anti-aging. CJC-1295 is not FDA-approved, it is not eligible for routine pharmacy compounding, and it is banned in sport.
At a glance
- FDA status
- Non-FDA-approved peptide sold in the wellness/gray market, not an approved medicine
- What it is
- GHRH analog ("growth hormone secretagogue"); a longer-acting "DAC" version and a short-acting "no-DAC" (modified GRF 1-29) version are both sold
- Research
- Human data limited to short studies of hormone levels; benefit for muscle, fat, or anti-aging is unproven
- Sport
- Prohibited by WADA at all times
- Evidence strength
- Low research
Summary
CJC-1295 is a long-acting GHRH analog that raises growth hormone and IGF-1 levels. Learn what the research shows and why it is not FDA-approved.
What is CJC-1295?
CJC-1295 is an experimental peptide built on the growth-hormone-releasing hormone (GHRH) backbone, modified so it resists breakdown and lasts longer in the body. It is not an approved drug; it is sold through "research peptide" and wellness channels and marketed to boost the body's own growth hormone for muscle gain, fat loss, recovery, and "anti-aging."
Two versions circulate:
- CJC-1295 with DAC, a long-acting form that binds to blood albumin
- CJC-1295 without DAC, essentially "modified GRF 1-29"
In placebo-controlled human trials, the DAC form had an estimated half-life of 5.8 to 8.1 days.
How does it work?
The proposed mechanism is indirect. GHRH is the hypothalamic signal that tells the pituitary gland to release growth hormone in pulses. As a GHRH-receptor agonist, CJC-1295 is intended to amplify those pulses, raising growth hormone and, downstream, IGF-1. The marketed effects on body composition and recovery are inferred from that hormone rise rather than demonstrated directly. This describes the proposed pharmacology; whether it produces the claimed results in people is a separate question that controlled trials have not answered.
The best-characterized human data come from two randomized, placebo-controlled trials in healthy adults aged 21 to 61 (Teichman, 2006) and a follow-up analysis of healthy men aged 20 to 40.
| Measure | Study group | Finding |
|---|---|---|
| Mean growth hormone after one injection | Healthy adults aged 21 to 61 | Rose 2- to 10-fold for 6 days or more |
| Mean IGF-1 after one injection | Healthy adults aged 21 to 61 | Rose 1.5- to 3-fold |
| IGF-1 after repeat injections | Healthy adults aged 21 to 61 | Stayed elevated up to 28 days |
| Growth hormone pattern after a single injection | Healthy men aged 20 to 40 | Kept its pulsatile pattern |
| Trough levels over the same period | Healthy men aged 20 to 40 | Rose 7.5-fold |
Is it FDA-approved?
Safety note
Status: Non-FDA-approved peptide sold in the wellness/gray market, not an approved medicine
Category: Wellness and performance · Primary body area: Bones & muscles
No. CJC-1295 is not approved by the FDA for any use, and there is no approved CJC-1295 product. It is not eligible for routine 503A compounding: FDA lists it among substances whose compounding nominations were withdrawn. In sport, growth-hormone-releasing factors including GHRH analogs are prohibited at all times under the World Anti-Doping Agency (WADA) list.
What does the research show?
Editor’s note
Evidence strength: Low research (5 human · 0 animal/cell studies)
Human data are limited to short studies of hormone levels, with no controlled trials showing a benefit for the marketed muscle, fat-loss, recovery, or anti-aging uses.
The human evidence is limited to short pharmacology studies of hormone levels, not outcomes. According to PubMed, a Phase 1 study found CJC-1295 produced sustained, dose-dependent increases in growth hormone and IGF-1 and was described as well tolerated over the short term.
A related long-acting GHRH study reported similar hormone rises along with some impairment of glucose tolerance in older adults. These measure hormone levels, not muscle, fat, or recovery, and the short-acting "no-DAC" product sold online is largely uncharacterized in controlled human trials. There is no sound human evidence that it delivers the marketed wellness benefits.
CJC-1295 is often paired with ipamorelin, which acts at a separate receptor that growth hormone-releasing peptides (GHRPs) engage. No published human randomized controlled trial tests that combination as of September 2026.
Sources: a Phase 1 pharmacodynamic study of CJC-1295 (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006, DOI: 10.1210/jc.2005-1536) and a long-acting GHRH study (Munafò et al., European Journal of Endocrinology, 2005, DOI: 10.1530/eje.1.01965), both indexed on PubMed; and the WADA Prohibited List. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.
Registered human trials
5 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
Compare every peptide’s status in the peptide regulatory status database
More for Bones & muscles
View all bones & muscles peptides →- FDA-approved Bones & muscles
Abaloparatide
Abaloparatide is a synthetic 34-amino acid analog of parathyroid hormone-related protein (PTHrP) that activates the PTH1 receptor to stimulate new bone formation. FDA-approved in 2017 as Tymlos, it is a daily injection for postmenopausal women and men with osteoporosis at high fracture risk, and it is capped at two years of use. In the pivotal ACTIVE trial, it cut the risk of new spine fractures by about 86% versus placebo.
- FDA-approved Bones & muscles
Calcitonin-Salmon
Miacalcin (injection), nasal spray sold as a generic
Calcitonin-salmon is an FDA-approved synthetic version of a natural hormone that slows bone breakdown, used mainly for postmenopausal osteoporosis, Paget's disease of bone, and high blood calcium (hypercalcemia). It comes as an injection, sold as Miacalcin, and as a nasal spray sold as a generic. A modest effect on fractures and a small possible cancer risk with long-term use make it a second-line option today.
- FDA-approved Bones & muscles
Etelcalcetide
Etelcalcetide (sold as Parsabiv) is a peptide that activates the calcium-sensing receptor to lower parathyroid hormone, used for secondary hyperparathyroidism in people on dialysis for kidney disease. Unlike parathyroid hormone replacement, it suppresses an overactive parathyroid signal, and it is given intravenously at the end of each dialysis session. It has been FDA-approved in the U.S. since 2017.
- Not FDA-approved Bones & muscles
Follistatin-344
Follistatin-344 is a form of the natural protein follistatin that blocks myostatin, a brake on muscle growth, sold as a "research chemical" in the performance market for muscle gain. The strongest human data come from gene therapy, not the injectable peptide. In a small 2017 trial, six patients with sporadic inclusion body myositis gained a median 56.0 m per year on the 6-minute walk test after follistatin gene therapy, versus a 25.8 m decline in eight matched untreated controls (p = 0.01). It is not FDA-approved and is banned in sport.
- Not FDA-approved Bones & muscles
Ghrp-2
Pralmorelin
GHRP-2 (pralmorelin) is a synthetic ghrelin-mimic peptide that prompts the pituitary to release growth hormone, sold in the wellness market for muscle, recovery, and appetite. Its only genuine validated use is as a diagnostic test of growth hormone capacity (approved in Japan), not as a treatment, and there are no controlled trials supporting the marketed wellness benefits. As of 2026 it is not FDA-approved and is banned in sport.
- Not FDA-approved Bones & muscles
Ghrp-6
GHRP-6 is one of the original synthetic ghrelin-mimic peptides, sold in the wellness market to raise the body's own growth hormone and stimulate appetite. Human data are limited to short studies of growth hormone release, with no controlled trials proving the marketed muscle, recovery, or anti-aging benefits. As of 2026 it is not FDA-approved and is banned in sport.